These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21223357)

  • 1. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment.
    Polasek TM; Lin FP; Miners JO; Doogue MP
    Br J Clin Pharmacol; 2011 May; 71(5):727-36. PubMed ID: 21223357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP-mediated clozapine interactions: how predictable are they?
    Chetty M; Murray M
    Curr Drug Metab; 2007 May; 8(4):307-13. PubMed ID: 17504220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
    Preskorn SH
    J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions.
    Hermann R; von Richter O
    Planta Med; 2012 Sep; 78(13):1458-77. PubMed ID: 22855269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
    Derks M; Fowler S; Kuhlmann O
    Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities.
    Kosugi Y; Hirabayashi H; Igari T; Fujioka Y; Hara Y; Okuda T; Moriwaki T
    Xenobiotica; 2012 Feb; 42(2):127-38. PubMed ID: 22117526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome-P450-Mediated Drug
    Steyn SJ; Varma MVS
    Mol Pharm; 2020 Aug; 17(8):3024-3032. PubMed ID: 32589434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4.
    Mouly S; Meune C; Bergmann JF
    Intensive Care Med; 2009 Mar; 35(3):417-29. PubMed ID: 19132343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach.
    Rodrigues AD
    Drug Metab Lett; 2007 Jan; 1(1):31-5. PubMed ID: 19356015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.
    Yu J; Zhou Z; Tay-Sontheimer J; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2018 Jun; 46(6):835-845. PubMed ID: 29572333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach.
    Wang L; Shendre A; Chiang CW; Cao W; Ning X; Zhang P; Zhang P; Li L
    Br J Clin Pharmacol; 2022 Feb; 88(4):1471-1481. PubMed ID: 33543792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Informative Are Drug-Drug Interactions of Gene-Drug Interactions?
    Lagishetty CV; Deng J; Lesko LJ; Rogers H; Pacanowski M; Schmidt S
    J Clin Pharmacol; 2016 Oct; 56(10):1221-31. PubMed ID: 27040602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel.
    Tornio A; Filppula AM; Backman JT
    Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():48-59. PubMed ID: 34410044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.
    Schoretsanitis G; de Leon J; Eap CB; Kane JM; Paulzen M
    CNS Drugs; 2019 Dec; 33(12):1201-1222. PubMed ID: 31776871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
    Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
    Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
    Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
    Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.